Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction-Reference-Cited by-同舟云学术

Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction

Published:2022-06 Issue: Volume:236 Page:114343
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Le Biannic Raphaël,Magnez Romain^ORCID,Klupsch Frédérique^ORCID,Leleu-Chavain Natascha^ORCID,Thiroux Bryan,Tardy Morgane^ORCID,El Bouazzati Hassiba,Dezitter Xavier^ORCID,Renault Nicolas^ORCID,Vergoten Gérard,Bailly Christian,Quesnel Bruno,Thuru Xavier^ORCID,Millet Régis

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference49 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA;Sung;Cancer J. Clin.,2021

2. PD-1/PD-L1 pathway: current researches in cancer;Han;Am. J. Cancer Res.,2020

3. Drug resistance in cancer: an overview;Housman;Cancers,2014

4. PD-L1 distribution and perspective for cancer immunotherapy—blockade, knockdown, or inhibition;Wu;Front. Immunol.,2019

5. Immune Checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy;Lee;J. Clin. Pharmacol.,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activity of pyridyl-pyrazolone derivatives against Trypanosoma cruzi;Experimental Parasitology;2024-07

2. Comparative Analysis of the Techniques for the Determination of Binding Affinity between a Small Molecule Inhibitor and a Protein Target;2024-05-16

3. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Frontiers in Immunology;2024-04-10

4. Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest;Journal of Inorganic Biochemistry;2024-01

5. Progress in small-molecule inhibitors targeting PD-L1;RSC Medicinal Chemistry;2024